I write about applied AI, governance, and the integration work that determines whether AI reaches production.
Selected pieces
Five pieces covering the questions I am asked most: what survives diligence, why pilots fail, and what it takes to run AI inside a regulated business. Each extract is the piece's own opening; the full text is on Substack.
What survives diligence in healthcare AI, and what it takes to build it after the close.
Read the pieceHealthcare private equity is paying for AI. The sector set a record in 2025, with Bain counting about $191 billion in disclosed deal value across roughly 445 buyouts, with exits rebounding to $156 billion from $54 billion the year before.
The fund that treats AI as a cost lever will be holding pilots in 2028.
Read the pieceI tried to build a real AI lab at Resmed and the first version failed.
Health equity, chronic disease, and what AI can really fix.
Read the pieceWhen people hear that I work on artificial intelligence (AI) in healthcare, the question I get more and more is: “Is AI actually going to fix health inequity—or just give nicer tools to people who are already well served?”
Aging in the era of multimodal AI.
Read the pieceBy the time I’m old enough for the senior menu, my android co-author will almost certainly have followed me home.
The operating-system view of healthcare AI.
Read the pieceIf you sit in enough Board and ELT meetings, you start to hear the same line: “We’ve got lots of GenAI pilots running.” It sounds like progress. It usually isn’t.
These are the pieces I point people to. The rest of the archive, and everything new, lives on Substack.
Read on Substack →Speaking
On panels and stages, where the questions come without notice.
If something here maps to a problem you are weighing, the best first step is usually a short diagnosis.